Although half the patients (n = 2) did not have pretreatment samples, the remaining 2 patients (P16 and P17) likely acquired FGFR fusions as alternative mechanisms to combat the anti-tumor activity of EGFR TKIs (Table 2). This evidence concerns the gene EGFR and neoplasm.